We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
- Authors
Land, Stephanie R; Kopec, Jacek A; Cecchini, Reena S; Ganz, Patricia A; Wieand, H Samuel; Colangelo, Linda H; Murphy, Kate; Kuebler, J Philip; Seay, Thomas E; Needles, Burton M; Bearden, James D, 3rd; Colman, Lauren K; Lanier, Keith S; Pajon, Eduardo R, Jr; Cella, David; Smith, Roy E; O'Connell, Michael J; Costantino, Joseph P; Wolmark, Norman
- Abstract
The randomized, multicenter, phase III protocol C-07 compared the efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in stage II or III colon cancer. Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 16, p2205
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.08.6652